

Selected Multicenter Studies in Bone and Joint Disease with Resources Available through the Epidemiologic and Biostatistics Core

Study, (PI), Sponsor, Dates	RCT or Obs*	# of Participants (FU years) # of clinics	Biologic Specimens Available to Research Community		Images available to Research Community		Publication examples (approximate total pubs)
			Frozen Serum sample	Others	DXA	Others	
Study of Osteoporotic Fractures (SOF) (PI: Steven Cummings) NIAMS/NIA 1986-current	Obs	9704 (~120,000 py) 4	All women at baseline (BL) and periodic FU	DNA/GWAS Urine at BL	DXA on all women in 1988-89 and at periodic FU visits	Pelvic and spine x-rays at BL and at 2 FU visits. pQCT on sample	(>400)
Osteoporotic Fractures in Men Study (MrOS) (PI: Steven Cummings) NIAMS/NIA 1999-current	Obs	5,995 (~55,000 py) 6	All men at BL and periodic FU	DNA/GWAS Urine at BL	DXA on all men at BL and 2 FU visits.	Hip, spine QCT at BL on ~4000 men with ~600 FU. Spine x-rays on all at BL and 5 yr FU	(125)
Osteoarthritis Initiative (OAI) (PI: Michael Nevitt) NIAMS + Pharma 2002-current	Obs	4,796 (~35,000 py) 5	samples on all at BL and 12, 24, and 36 mo. FU	Plasma and urine samples on all at BL, 12, 24, 36 mo. FU	N/A	Knee MRI at BL on ~4876 at BL and annually through 48 mo. and at 72 mo	(>80)
Health, Aging and Body Composition (Health ABC) (Co-PI: Steven Cummings, Michael Nevitt) NIA 1996-current	Obs	3,075 (~30,000 py) 2	All participants at BL and at periodic FU visits through year 11	DNA/GWAS Urine & Plasma at BL and FU visits	Whole body & hip DXA at BL and at selected FU visits.	Knee MRI, Abd. and thigh CT, hip x-ray at BL and FU visits. QCT of spine in subset	(>350)
Multicenter Osteoarthritis Study (MOST) (PI: Michael Nevitt) NIA 2003-current	Obs	3,026 (~20,000) 2	3,026 at BL and 30+60 month FU	DNA Plasma, Urine, collected at various visits	Whole body and hip DXA at BL and 84-month	Knee MRI and x-rays at BL and 4 FU visits Full-limb x-rays at BL and 60-mo	(>50)
PTH and alendronate in combination for the treatment of osteoporosis (PaTH) (PI: Dennis Black) NIAMS 1999-2004	RCT	238 (~600 py) 4	Frozen samples on all at BL and several FU visits	Urine at BL and FU	DXA on all at BL, 6, 12 and 24 months.	Hip, spine QCT at BL and annually.	(>15)
HORIZON Pivotal Fracture Trial + extensions (PI: Dennis Black) Novartis 2001-current	RCT	7736 (~28,000 py) 235	~800 BL and annual FU visits	Urine ~ 650	Hip DXA on all (spine/wrist on sample) at BL and annually	Vertebral x-rays at BL and annual FU's ~7765	(>20)
PTH and Ibandronate Combined (PICS) (PI: Dennis Black) Roche/Genentech 2008-2012	RCT	44 (~90 py) 1	samples at BL and several FU visits	No	Hip/spine/WB at BL, 6, 12, 24 mos	QCT Hr-QCT MRI	(2)
Fracture Intervention Trial (FIT) (PI: Dennis Black) Merck 1991-1998	RCT	6,459 (~24,000 py) 11	All women at BL and at annual FU	Urine on all women at BL	Hip/spine DXA on all women at BL and annually. Wrist/WB on subsets	Vertebral x-rays at BL and at 2 FU visits	(>35)
FIT Long-Term Extension (FLEX) (PI: Dennis Black) Merck 1998-2003	RCT	1,099 (~5,000 py) 10	All women at BL and 3 and 5 year FU visits	Urine Frozen at BL	DXA on all women at BL and annually at FU.	Vertebral x-rays at BL and study end	(6)
Breast cancer and fracture f/up of the FIT screenees (B-FIT) (PI: Douglas Bauer) NCI 2000-2004	RCT/ Obs	22,000 (~140,000 py) 10	All women at FIT BL	DNA. Urine on ~2000 women at FIT BL	DXA (hip, spine) from FIT BL (~22,000)	Spine x-rays from FIT BL on sample (~10,000)	N/A

* Study design: Observational or Randomized, Controlled Trial